On the role of aggregates in the immunogenicity of recombinant human interferon beta in patients with multiple sclerosis

Journal of Interferon and Cytokine Research

Volumn 30, Issue 10, 2010, Pages 767-775

  Van Beers, Miranda M C ^a,b   Jiskoot, Wim ^b   Schellekens, Huub ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b LEIDEN UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; EXTAVIA; GLATIRAMER; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G4; INTERFERON BETA SERINE; MITOXANTRONE; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; ANTIBODY TITER; DRUG DOSE COMPARISON; GENE EXPRESSION; GLYCOSYLATION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOMODULATION; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; RELAPSE; REVIEW;

ANTIBODIES; ANTIBODIES, NEUTRALIZING; ANTIGEN-ANTIBODY REACTIONS; HUMANS; INTERFERON-BETA; MULTIPLE SCLEROSIS; RECOMBINANT PROTEINS;

EID: 77957367160     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.2010.0086     Document Type: Review

References (90)

1. Bachmann MF, Zinkernagel RM 1997. Neutralizing antiviral B cell responses. Annu Rev Immunol '15(1):235-270.
2. Baker DP, Lin EY, Lin K, Pellegrini M., Petter RC, Chen LL, Arduini RM, Brickelmaier M, Wen D., Hess DM, Chen L, Grant D, Whitty A, Gill A, Lindner DJ, Pepinsky RB. 2006. N-terminally PEGylated human interferon-beta-1a with improved pharmacokinetic properties and in vivo efficacy in a melanoma angiogenesis model. Bioconjug Chem '17(1): 179-188.
3. Bee JS, Chiu D, Sawicki S., Stevenson JL, Chatterjee K, Freund E, Carpenter J.F., Randolph TW. 2009. Monoclonal antibody interactions with micro- and nanoparticles: adsorption, aggregation, and accelerated stress studies. J Pharm Sci '98(9): 3218-3238.
4. Bellomi F, Scagnolari C, Tomassini V., Gasperini C, Paolillo A, Pozzilli C., Antonelli G. 2003. Fate of neutralizing and binding antibodies to IFN beta in MS patients treated with IFN beta for 6 years. J Neurol Sci '215(1-2):3-8.
5. Bertolotto A, Deisenhammer F, Gallo P., Sorensen PS 2004. Immunogenicity of interferon beta: differences among products. J Neurol 251 (SUPPL. 2):II15-II24.
6. Bertolotto A, Malucchi S, Milano E., Castello A, Capobianco M, Mutani R. 2000. Interferon beta neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations. Immunopharmacology '48(2):95-100.
7. Braun A, Kwee L, Labow M.A., Alsenz J. 1997. Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-alpha) in normal and transgenic mice. Pharm Res '14(10):1472-1478.
8. Byun E, Caillier SJ, Montalban X, Villoslada P., Fernandez O, Brassat D, Comabella M., Wang J, Barcellos LF, Baranzini SE, Oksenberg JR. 2008. Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis. Arch Neurol '65(3):337-344.
9. Carpenter JF, Randolph TW, Jiskoot W, Crommelin DJA, Middaugh CR, Winter G, Fan Y-X, Kirshner S, Verthelyi D, Kozlowski S, Clouse KA, Swann PG, Rosenberg A. Cherney B. 2009. Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality. J Pharm Sci '98(4):1201-1205.
10. Casadevall N, Nataf J, Viron B., Kolta A, Kiladjian J-J, Martin-Dupont P, Michaud P., Papo T, Ugo V, Teyssandier I, Varet B, Mayeux P. 2002. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med '346(7):469-475. (Pubitemid 34441737)
11. Chackerian B, Lenz P, Lowy D.R., Schiller JT 2002. Determinants of autoantibody induction by conjugated papillomavirus virus-like particles. J Immunol '169(11):6120-6126.
12. Clanet M, Radue EW, Kappos L, Hartung H.P., Hohlfeld R., Sandberg-Wollheim M, Kooijmans-Coutinho MF, Tsao E.C., Sandrock AW; European IFNbeta-1a (Avonex) Dose-Comparison Study Investigators. 2002. A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS. Neurology '59(10):1507-1517.
13. Cleland JL, Rosendahl M, Eisenberg S.P., Seefeldt M., Haughey D. 2008. BaroFeron, a more bioavailable and less immunogenic IFN beta product. The Consortium of Multiple Sclerosis Centers (CMSC). Abstract number S12. Available at http://annualmeeting.mscare.org/. Accessed on 24 August 2010.
14. Comabella M, Lunemann JD, Rio J, Sanchez A., Lopez C, Julia E, Fernandez M., Nonell L, Camina-Tato M, Deisenhammer F, Caballero E, Tortola MT, Prinz M. Montalban X, Martin R. 2009. A type I interferon signature in monocytes is associated with poor response to interferon-β in multiple sclerosis. Brain '132(12):3353-3365.
15. Conway D, Cohen JA 2010. Combination therapy in multiple sclerosis. Lancet Neurol '9(3):299-308.
16. Deisenhammer F, Reindl M, Berger T. 2001. Immunoglobulin subclasses in patients with neutralizing and nonneutralizing antibodies against IFN-beta1b. J Interferon Cytokine Res '21(3): 167-171.
17. Dintzis HM, Dintzis RZ, Vogelstein B. 1976. Molecular determinants of immunogenicity: the immunon model of immune response. Proc Natl Acad Sci U S A '73(10):3671-3675.
18. Doggrell SA. 2010. Good results for early treatment of clinically isolated syndrome prior to multiple sclerosis with interferon beta-1b and glatiramer group. Expert Opin Pharmacother '11(7):1225-1230.
19. Dresser DW. 1962. Specific inhibition of antibody production. II. Paralysis induced in adult mice by small quantities of protein antigen. Immunology '5:378-388.
20. European Study Group on Interferon Beta-1b in Secondary Progressive MS. 1998. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet '352(9139): 1491-1497.
21. Farrell RA, Giovannoni G. 2007. Measuring and management of anti-interferon beta antibodies in subjects with multiple sclerosis. Mult Scler '13(5):567-577.
22. FDA. 1993. Center for Drug Evaluation and Research. Drugs@FDA online database. Approval letter 1993 BETA-SERON application no. 103471. Available at www.accessdata.fda.gov/drugsatfda-docs/nda/pre96/103471s0000-APPROV.pdf (accessed 03/08/10).
23. Files JG, Hargrove D, Delute L., Cantillon M. 2007. Measured neutralizing titers of IFN-beta neutralizing antibodies (NAbs) can depend on the preparations of IFN-beta used in the assay. J Interferon Cytokine Res '27(8):637-642.
24. Filipe V, Hawe A, Schellekens H., Jiskoot W. 2010. Aggregation and immunogenicity of therapeutic proteins. In: Wang W, Roberts CJ, eds. Aggregation of therapeutic proteins. Hoboken (NJ): John Wiley & Sons. pp 403-433.
25. Francis GS, Rice GPA, Alsop JC; PRISMS Study Group. 2005. Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS. Neurology '65(1):48-55.
26. Gilli F, Hoffmann F, Sala A., Marnetto F, Caldano M, Valentino P., Kappos L, Bertolotto A, Lindberg RL. 2006. Qualitative and quantitative analysis of antibody response against IFNbeta in patients with multiple sclerosis. Mult Scler '12(6):738-746.
27. Gilli F, Valentino P, Caldano M., Granieri L, Capobianco M, Malucchi S., Sala A, Marnetto F, Bertolotto A. 2008. Expression and regulation of IFNalpha/beta receptor in IFNbeta-treated patients with multiple sclerosis. Neurology '71(24): 1940-1947.
28. Giovannoni G, Munschauer F. 3rd, Deisenhammer F. 2002. Neutralising antibodies to interferon beta during the treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry '73(5):465-469.
29. Gneiss C, Reindl M, Lutterotti A., Ehling R, Egg R, Khalil M., Berger T, Deisenhammer F. 2004. Interferon-beta: the neutralizing antibody (NAb) titre predicts reversion to NAb negativity. Mult Scler '10(5):507-510.
30. Gneiss C, Tripp P, Reichartseder F., Egg R, Ehling R, Lutterotti A., Khalil M, Kuenz B, Mayringer I, Reindl M, Berger T, Deisenhammer F. 2006. Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients. Mult Scler '12(6):731-737.
31. Grossberg SE, Kawade Y, Kohase M., Klein JP 2001. The neutralization of interferons by antibody. II. Neutralizing antibody unitage and its relationship to bioassay sensitivity: the tenfold reduction unit. J Interferon Cytokine Res '21(9):743-755.
32. Hartung HP, Munschauer F 3rd, Schellekens H. 2005. Significance of neutralizing antibodies to interferon beta during treatment of multiple sclerosis: expert opinions based on the Proceedings of an International Consensus Conference. Eur J Neurol '12(8):588-601.
33. Hartung HP, Polman C, Bertolotto A., Deisenhammer F, Giovannoni G, Havrdova E., Hemmer B, Hillert J, Kappos L, Kieseier B, Killestein J, Malcus C, Comabella M, Pachner A, Schellekens H, Sellebjerg F, Selmaj K, Sorensen PS. 2007. Neutralising antibodies to interferon beta in multiple sclerosis: expert panel report. J Neurol '254(7):827-837.
34. Hawe A, Friess W. 2008. Development of HSA-free formulations for a hydrophobic cytokine with improved stability. Eur J Pharm Biopharm '68(2):169-182.
35. Hemmer B, Stüve O, Kieseier B., Schellekens H, Hartung H-P. 2005. Immune response to immunotherapy: the role of neutralising antibodies to interferon beta in the treatment of multiple sclerosis. Lancet Neurol '4(7):403-412.
36. Hermeling S, Aranha L, Damen JMA, Slijper M, Schellekens H., Crommelin DJA, Jiskoot W. 2005a. Structural characterization and immunogenicity in wild-type and immune tolerant mice of degraded recombinant human interferon alpha2b. Pharm Res '22(12):1997-2006.
37. Hermeling S, Crommelin D, Schellekens H., Jiskoot W. 2004. Structure-immunogenicity relationships of therapeutic proteins. Pharm Res '21(6):897-903.
38. Hermeling S, Jiskoot W, Crommelin DJA, Bornæs C, Schelle-kens H. 2005b. Development of a transgenic mouse model immune tolerant for human interferon beta. Pharm Res '22(6): 847-851.
39. Hermeling S, Schellekens H, Maas C., Gebbink MFBG, Crommelin DJA, Jiskoot W. 2006. Antibody response to aggregated human interferon alpha2b in wild-type and transgenic immune tolerant mice depends on type and level of aggregation. J Pharm Sci '95(5):1084-1096.
40. *0408 are strongly associated with the development of antibodies against interferon-beta therapy in multiple sclerosis. Am J Hum Genet '83(2):219-227.
41. Hurwitz BJ. 2008. Important sources of variability in clinical studies of neutralizing antibodies against interferon beta. J Neurol Sci '272(1-2):8-19.
42. The IFNB Multiple Sclerosis Study Group. 1993. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology '43(4):655-661.
43. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. 1996. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology '47(4):889-894.
44. Jaber A, Baker M. 2007. Assessment of the immunogenicity of different interferon beta-1a formulations using ex vivo T-cell assays. J Pharm Biomed Anal '43(4):1256-1261.
45. Jacobs LD, Beck RW, Simon J.H., Kinkel RP, Brownscheidle CM, Murray TJ, Simonian N.A., Slasor PJ, Sandrock AW; CHAMPS Study Group. 2000. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med '343(13):898-904.
46. Jones WE, Quigley K, Parish T.H., Goelz SE 1998. Evaluation of interferon-beta immunogenicity in mice. Neurology 50 (SUPPL. 4):A34.
47. Kappos L, Clanet M, Sandberg-Wollheim M, Radue E.W., Hartung HP, Hohlfeld R, Xu J, Bennett D., Sandrock A, Goelz S. European Interferon Beta-1a IM Dose-Comparison Study Investigators. 2005. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. Neurology '65(1): 40-47.
48. Karpusas M, Nolte M, Benton C.B., Meier W., Lipscomb WN, Goelz S. 1997. The crystal structure of human interferon-beta at 2.2-Å resolution. Proc Natl Acad Sci U S A '94(22):11813-11818.
49. Karpusas M, Whitty A, Runkel L., Hochman P. 1998. The structure of human interferon-beta: implications for activity. Cell Mol Life Sci '54(11):1203-1216.
50. Kivisäkk P., Alm GV, Fredrikson S, Link H. 2000. Neutralizing and binding anti-interferon-beta-1a antibodies. A comparison between IFN-beta-1a and IFN-beta-1b treatment in multiple sclerosis. Eur J Neurol '7(1):27-34.
51. Knobler RL, Greenstein JI, Johnson K.P., Lublin FD, Panitch HS, Conway K, Grant-Gorsen SV, Muldoon J., Marcus SG, Wallenberg JC, Williams GJ, Yoshizawa CN. 1993. Systemic recombinant human interferon-beta treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up. J Interferon Res '13(5):333-340.
52. Lallemand C, Meritet J-F, Blanchard B, Lebon P., Tovey MG. 2010. One-step assay for quantification of neutralizing antibodies to biopharmaceuticals. J Immunol Methods 356 (1-2):18-28.
53. Millonig A, Rudzki D, Holzl M., Ehling R, Gneiss C, Kunz B., Berger T, Reindl M, Deisenhammer F. 2009. High-dose intravenous interferon beta in patients with neutralizing antibodies (HINABS): a pilot study. Mult Scler '15(8):977-983.
54. Moore WV, Leppert P. 1980. Role of aggregated human growth hormone (hGH) in development of antibodies to hGH. J Clin Endocrinol Metab 51(4):691-697.
55. OWIMS Study Group. 1999. Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study. Neurology '53(4):679-686.
56. Parnham MJ, Schindler-Horvat J, Kozlovi M. 2007. Non-clinical safety studies on biosimilar recombinant human erythropoietin. Basic Clin Pharmacol Toxicol '100(2):73-83.
57. Peng A, Gaitonde P, Kosloski M.P., Miclea RD, Varma P, Balu-Iyer SV. 2009. Effect of route of administration of human recombinant factor VIII on its immunogenicity in Hemophilia A mice. J Pharm Sci '98(12):4480-4484.
58. Perini P, Facchinetti A, Bulian P., Massaro AR, De Pascalis D, Bertolotto A, Biasi G., Gallo P. 2001. Interferon-beta (INF-beta) antibodies in interferon-beta1a- and interferon-beta1b-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-beta immunogenicity in vivo. Eur Cytokine Netw '12(1):56-61.
59. Petersen B, Bendtzen K, Koch-Henriksen N, Ravnborg M., Ross C, Sorensen PS; The Danish Multiple Sclerosis Group. 2006. Persistence of neutralizing antibodies after discontinuation of IFNbeta therapy in patients with relapsing-remitting multiple sclerosis. Mult Scler '12(3):247-252.
60. Ponce R, Abad L, Amaravadi L., Gelzleichter T, Gore E, Green J., Gupta S, Herzyk D, Hurst C, Ivens IA, Kawabata T. Maier C, Mounho B, Rup B, Shankar G, Smith H, Thomas P, Wierda D. 2009. Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies. Regul Toxicol Pharmacol '54(2): 164-182.
61. PRISMS Study Group. 1998. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet '352(9139):1498-1504.
62. Radue E-W, Stuart W.H., Calabresi PA, Confavreux C, Galetta SL, Rudick R.A., Lublin FD, Weinstock-Guttman B, Wynn DR, Fisher E, Papadopoulou A, Lynn F, Panzara MA, Sandrock AW; SENTINEL Investigators. 2010. Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis. J Neurol Sci '292(1-2):28-35.
63. Rosenberg AS. 2006. Effects of protein aggregates: an immunologic perspective. AAPS J 8(3):E501-E507.
64. Ross C, Clemmesen KM, Svenson M, Sørensen PS, Koch-Henriksen N, Skovgaard GL, Bendtzen K. 2000. Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group. Ann Neurol '48(5): 706-712.
65. Rudick R, Simonian N, Alam J., Campion M, Scaramucci J, Jones W., Coats M, Goodkin D, Weinstock-Guttman B, Herndon R, Mass M, Richert J, Salazar A, Munschauer FR, Cookfair D, Simon J, Jacobs L. 1998. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology '50(5):1266-1272. (Pubitemid 28240338)
66. Rudick RA. 2003. Biologic impact of interferon antibodies, and complexities in assessing their clinical significance. Neurology 61 (SUPPL. 5):S31-S34.
67. Runkel L, Meier W, Pepinsky R.B., Karpusas M., Whitty A, Kimball K, Brickelmaier M., Muldowney C, Jones W, Goelz SE. 1998. Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN-beta). Pharm Res 15(4):641-649.
68. Sauerborn M, Brinks V, Jiskoot W., Schellekens H. 2010. Immunological mechanism underlying the immune response to recombinant human protein therapeutics. Trends Pharmacol Sci '31(2):53-59.
69. Sbardella E, Tomassini V, Gasperini C., Bellomi F, Cefaro L, Morra V., Antonelli G, Pozzilli C. 2009. Neutralizing antibodies explain the poor clinical response to Interferon beta in a small proportion of patients with multiple sclerosis: a retrospective study. BMC Neurol '9(1):54.
70. Schellekens H. 2002a. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discov '1(6):457-462.
71. Schellekens H. 2002b. Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin Ther '24(11): 1720-1740.
72. Schellekens H. 2008. How to predict and prevent the immunogenicity of therapeutic proteins. Biotechnol Annu Rev '14:191-202.
73. Seefeldt MB, Boux H, Cleland JL 2008. Reduced aggregate levels and immunogenicity of murine interferon beta treated with high pressure. AAPS J 10(S1). Abstract number NBC08-000794. Available at www.aapsj.org/. Accessed on 24 August 2010.
74. Shapiro AM, Jack CS, Lapierre Y, Arbour N., Bar-Or A, Antel JP 2006. Potential for interferon beta-induced serum antibodies in multiple sclerosis to inhibit endogenous interferon-regulated chemokine/cytokine responses within the central nervous system. Arch Neurol '63(9):1296-1299.
75. Sominanda A, Hillert J, Fogdell-Hahn A. 2009. Neutralizing antibodies against interferon beta: fluctuation is modest and titre dependent. Eur J Neurol '16(1):21-26.
76. Sominanda A, Rot U, Suoniemi M., Deisenhammer F, Hillert J, Fogdell-Hahn A. 2007. Interferon beta preparations for the treatment of multiple sclerosis patients differ in neutralizing antibody seroprevalence and immunogenicity. Mult Scler '13(2):208-214.
77. Sorensen PS. 2008a. Can we spot the IFNbeta nonresponders? Neurology '71(24):1936-1937.
78. Sorensen PS. 2008b. Neutralizing antibodies against interferon-beta [Review]. Ther Adv Neurol Disord '1(2):125-141.
79. Sorensen PS, Koch-Henriksen N, Flachs E.M., Bendtzen K. 2008. Is the treatment effect of IFN-beta restored after the disappearance of neutralizing antibodies? Mult Scler 14(6):837-842.
80. Sorensen PS, Koch-Henriksen N, Ross C., Clemmesen KM, Bendtzen K. Danish Multiple Sclerosis Study Group. 2005. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology '65(1):33-39.
81. Sorensen PS, Ross C, Clemmesen K.M., Bendtzen K., Frederiksen JL, Jensen K, Kristensen O, Petersen T., Rasmussen S, Ravnborg M, Stenager E, Koch-Henriksen N; Danish Multiple Sclerosis Study Group. 2003. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet '362(9391):1184-1191.
82. SPECTRIMS Study Group. 2001. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results. Neurology '56(11):1496-1504.
83. Spiegel RJ. 1989. Alpha interferons: a clinical overview. Urology 34 (SUPPL. 1):75-79.
84. Tracey D, Klareskog L, Sasso E.H., Salfeld JG, Tak PP 2008. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther '117(2):244-279.
85. van Baarsen LGM, Vosslamber S, Tijssen M, Baggen JMC, van der Voort LF, Killestein J, van der Pouw Kraan TCTM, Polman CH, Verweij CL. 2008. Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients. PLoS ONE 3(4):e1927.
86. van Beers MMC, Sauerborn M, Gilli F, Hermeling S, Schellekens H, Jiskoot W. 2010. Hybrid transgenic immune tolerant mouse model for assessing the breaking of B cell tolerance by human interferon beta. J Immunol Methods 352(1-2): 32-37.
87. Vandenbroeck K, Matute C. 2008. Pharmacogenomics of the response to IFN-beta in multiple sclerosis: ramifications from the first genome-wide screen. Pharmacogenomics '9(5): 639-645.
88. Wang C, Eufemi M, Turano C., Giartosio A. 1996. Influence of the carbohydrate moiety on the stability of glycoproteins. Biochemistry '35(23):7299-7307. (Pubitemid 26189798)
89. White PJ, Anastasopoulos F, Church J.E., Kuo CY, Boyd BJ, Hickey PLC, Tu LS, Burns P, Lew AM, Heath WR, Davey GM, Pouton CW. 2008. Generic construction of single component particles that elicit humoural and cellular immune responses without the need for adjuvants. Vaccine '26(52):6824-6831.
90. Yeung VP, Chang J, Miller J., Barnett C, Stickler M, Harding FA 2004. Elimination of an immunodominant CD4+ T cell epitope in human IFN-beta does not result in an in vivo response directed at the subdominant epitope. J Immunol '172(11):6658-6665.